Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Acute myocardial infarction (AMI) therapy has not remarkably improved due to delay in the diagnosis to a great extent. Circulating microRNAs have shown some potential for diagnosis of cardiovascular diseases. The aim of this study was to estimate the diagnostic value of circulating miR-126-3p for AMI. In our study, circulating miR-126-3p levels were determined by quantitative polymerase chain reaction and the results showed it was 106-fold higher than that in controls, and elevated miR-126-3p was associated with aging through logistic correlation analyses. Receiver-operator characteristic curve was used to evaluate the sensitivity and specificity of miR-126-3p for diagnosis of AMI, indicating that its diagnostic effect was superior to the current clinical markers such as CK, CK-MB, hs-TnI, and MYO. Our results indicate that miR-126-3p in circulation is a potential novel diagnostic biomarker for AMI.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965822 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Background: At present, existing risk scores together with traditional biomarkers such as troponin and brain natriuretic peptide (BNP) are still unable to accurately predict cancer therapy-related cardiac dysfunction (CTRCD). MicroRNAs (miRNAs) have emerged as promising biomarkers for improved identification of high-risk patients; however, limited studies have been performed in patients with HER2-positive breast cancer.
Objectives: To investigate the predictive potential of six serum-derived circulating miRNAs for CTRCD occurrence in patients with early-stage HER2-positive breast cancer receiving trastuzumab (TTZ).
Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study.
NPJ Precis Oncol
August 2025
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.
Circulating microRNAs (miRNAs) have not been investigated as predictive biomarkers in patients with advanced biliary tract cancer (ABTC) who received chemoimmunotherapy. In the single-arm phase II T1219 trial, 46 patients with ABTC received first-line nivolumab, gemcitabine, and S-1 treatment. Plasma samples were prospectively collected at baseline and 6 weeks after treatment for miRNA profiling.
View Article and Find Full Text PDFBridging the gaps in detection of structural cardiotoxicity in stem cell-derived cardiomyocytes: promise of miR-133b, miR-184 and miR-208b-3p.
Front Pharmacol
July 2025
UCB Biopharma SRL, Non-Clinical Safety Evaluation, Braine-L'Alleud, Belgium.
Introduction: Drug-induced cardiotoxicity is one of the main causes of attrition due to safety in preclinical and clinical development; therefore, identifying novel assays and/or biomarkers to detect potentially harmful candidates is pivotal for the pharmaceutical industry. Over the past decade, microRNAs (miRNAs) have been proposed as alternative translatable biomarkers for cardiotoxicity. Although miRNAs could be useful for detection of cardiotoxicity, they are not routinely assessed in preclinical drug development.
View Article and Find Full Text PDFEffect of Topical Corticosteroid Treatment on microRNA Expression in Infants with Atopic Dermatitis.
JID Innov
September 2025
Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
MicroRNAs (miRNAs) have been implicated in a variety of disorders. Although studies have examined miRNA in pediatric atopic dermatitis (AD), the impact of topical corticosteroid (TCS) therapy on miRNA expression in pediatric AD has not been investigated. We sought to investigate the effects of 6 weeks of TCS therapy on miRNA expression in infants with AD.
View Article and Find Full Text PDFCirculating MicroRNAs Associated with Changes in the Placenta and Their Possible Role in the Fetus During Gestational Diabetes Mellitus: A Review.
Metabolites
June 2025
Molecular Biology Research Laboratory, Children's Hospital of Mexico Federico Gomez (HIMFG), Mexico City C.P. 06720, Mexico.
Unlabelled: MicroRNAs (miRs) are epigenetic regulators of several metabolic diseases, including gestational diabetes mellitus (GDM).
Objectives: Following a systematic review, we propose a pattern of key circulating miRs associated with placental changes and their potential role in the fetus.
Methods: A systematic investigation of studies published between January 2011 and July 2024 was conducted in the PubMed, ScienceDirect, Trip Database, and Wiley databases.